Qualia Life Sciences, Award-Winning Supplement Brand, Celebrates Its 10th Year Anniversary
With Human Studies On Every Formula, Qualia's Industry-Leading Research Standards Are Fueling Innovation and Rapid GrowthCARLSBAD, Calif., Dec. 9, 2025...
Brain
Sage Growth Partners Honored for Healthcare Marketing Campaign of the Year at 2025 PR Daily Awards
Annual awards recognize industry's most successful campaigns, initiatives, people, and teamsBALTIMORE, Dec. 9, 2025 /PRNewswire/ -- Sage Growth Partners (Sage), a...
Neurophet Introduced Use Cases of Its AI-based Brain Imaging Analysis Solutions at the SEACURE Symposium Hosted by Nanyang Technological University in Singapore
Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer's disease treatmentsHighlighted clinical...
Results from Phase 1 Multiple-Dose Study of PT00114
Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW...
MJFF Initiates Funding for Emerging Therapeutic Targets in Parkinson’s Disease
NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced the initiation of...
Clinical Communication & Collaboration Market worth $5,302.9 million by 2030 | MarketsandMarkets™
DELRAY BEACH, Fla., Dec. 8, 2025 /PRNewswire/ -- According to MarketsandMarkets™, the Clinical Communication & Collaboration Market is projected to grow...
Abbott’s Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data
Lingo, Abbott's first over-the-counter biowearable, expands to Android devicesContinuous glucose monitoring devices help people maintain healthy glucose levels, which are...
Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings,...
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression...
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active...
Neurophet Participates RSNA 2025, Showcased Real-World Clinical Use Cases of ‘Neurophet AQUA AD’
Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatmentsHighlighted...
November in Review: 10 Top Health Press Releases
A roundup of the most newsworthy healthcare press releases from PR Newswire, including new company mergers, Alzheimer's fundraising and advances...
Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF
BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A recent setback due to unexpected safety concern from a phase 2 study...
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)...
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire...
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapiesCREXONT delivered substantial “Off” time reductions,...
mlHealth 360 Receives FDA Clearance for Scaida BrainCT-ICH: Canada’s First AI Solution for Intracranial Hemorrhage Triage
Major Regulatory Milestone: The first Canadian-developed AI for ICH triage receives FDA clearance to enter the U.S. market.Operational Value: Automates...
UofL’s 2026 Grawemeyer psychology award winner recognized for contributions to autism research
LOUISVILLE, Ky., Dec. 4, 2025 /PRNewswire/ -- Sir Simon Baron-Cohen has received the 2026 Grawemeyer Award in Psychology, a distinction...
Diagonal Therapeutics to Present Insights from HHT IMPACT, a Natural History Study Initiated in Partnership with Cure HHT, at ASH 2025
Preliminary results indicate HHT patients are significantly impacted by bleeding events, with consistency in severity reporting at months one and...
BTT Medical Institute Announces Unprecedented Case of Total Reversal of ALS through Re-engineering of the Nobel Prize-Winning Fever Therapy into a Brain-Guided, Artificial Intelligence-Controlled ThermoFebrile Treatment
First video-documented ALS reversal marks a new era for brain health achieved through noninvasive computerized brain-temperature modulation, confirmed by electrophysiological,...